Streetbeat News

OSCR

Oscar Health, Inc.

https://www.hioscar.com

Industry

Medical - Healthcare Plans

Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payor clients to engage with members and patients. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

Open

15.53

Mkt cap

3.1B

Volume

High

15.70

P/E Ratio

-743.50

52-wk high

23.79

Low

14.23

Div yield

N/A

52-wk low

7.16

Oscar Health (OSCR) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects. This upgrade suggests potential positive movement in OSCR's stock price.

Portfolio Pulse from

November 11, 2024 | 6:15 pm

Oscar Health, Inc. (OSCR) held its Q3 2024 earnings conference call on November 7, 2024. Key participants included CEO Mark Bertolini and CFO Scott Blackley. The call involved discussions with analysts from Wells Fargo, Raymond James, Piper Sandler, Nephron Research, Baird, and Bank of America.

Portfolio Pulse from

November 09, 2024 | 5:15 pm

Oscar Health, Inc. (OSCR) reported a Q3 loss of $0.22 per share, slightly worse than the Zacks Consensus Estimate of a $0.20 loss. However, the company topped revenue estimates.

Portfolio Pulse from

November 07, 2024 | 1:30 pm

Oscar Health is expanding its ACA plans for 2025, introducing affordable health insurance products and a new Spanish-language solution, Buena Salud. The company aims to provide personalized healthcare options across 504 markets in 18 states, focusing on diverse communities and chronic condition management.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 10:47 am

Oscar Health shares are trading lower following UBS's initiation of coverage with a Neutral rating and a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 4:41 pm

Oscar Health (NYSE:OSCR) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target remains at $26.0. Analysts have maintained or raised their ratings, reflecting a stable outlook. Despite positive revenue growth, Oscar Health faces challenges with net margins but shows strong ROE and ROA.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 4:01 pm

UBS has initiated coverage on Oscar Health with a Neutral rating and set a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 3:28 pm

Several stocks saw significant gains on Wednesday despite a general market downturn. Petco Health and Wellness (WOOF) rose 8.4% despite reporting larger-than-expected losses. PureCycle Technologies (PCT) jumped 20% following a financing announcement. Sigma Lithium (SGML), Lithium Americas (LAAC), and Albemarle (ALB) gained due to a rise in lithium prices. Hyliion Holdings (HYLN) rose after securing a Navy contract. Dave & Buster’s (PLAY) increased after better-than-expected earnings. AppLovin (APP) gained following a price target increase by B of A Securities.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 2:19 pm

Oscar Health (NYSE:OSCR) has received recent analyst ratings, all of which are somewhat bullish. The average 12-month price target is $26.5, reflecting a slight increase from previous targets. Oscar Health has shown significant revenue growth but lags behind industry peers in net margin. The company demonstrates strong financial management with a high ROE and low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 4:00 pm

Piper Sandler analyst Jessica Tassan has reiterated an Overweight rating on Oscar Health (NYSE:OSCR) and maintained a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.